Methods

Data search
We searched the following electronic databases from inception to May 2007: MEDLINE, EMBASE, The Cochrane Central Register of Controlled Trials and CINAHL. The search terms were combined into a single phrase "fish and implantable cardioverter defibrillator and arrhythmia." The search was restricted to English language articles; however, when the language restriction was removed, we did not identify any additional trials. The search was performed independently by 2 of us (A.R.J. and R.L.).
Selection
We included randomized controlled trials that evaluated fishoil supplementation in patients with implantable cardioverter defibrillators to prevent the recurrence of ventricular arrhythmia. We included studies where the intervention was consumption of fish-oil capsules (any dose). We excluded nonrandomized trials, letters and reviews; studies of atrial fibrillation or tachycardia and ventricular arrhythmia that did not involve implantable cardioverter defibrillators; and studies of fish-oil given as infusions or consumed as fatty fish. We selected studies involving patients with implantable cardioverter defibrillators because these patients are at high risk for ventricular tachycardia and fibrillation and because these studies provide a good model to study the potential antiarrhythmic effects of fish oil. Furthermore, implantable cardioverter defibrillators allow data to be gathered under controlled conditions over extended periods of supplementation with fish oils and provide an accurate reading of time to first event because of the long-term storage of electrocardio-graphic data. In contrast, an arrhythmic cause of death is difficult to infer from the history of patients without implantable cardioverter defibrillators.
Validity assessment
We used the Jadad Score to assess the methodologic quality of the included studies, 15 and the Cochrane Collaboration Scale to rate study validity.
Data extraction
Data were extracted independently and in duplicate by 2 of us (A.R.J., D.J.A.J.). Extraction was verified by the study statistician (J.B.). All disagreements were resolved by consensus.
Quantitative data synthesis
Two of the trials reported hazard ratios 12,14 and 1 reported relative risk [RR]; 13 thus, we calculated RR for outcomes at 1year follow-up. We synthesized the outcome data using RR as the effect measure, and we examined heterogeneity using the Q test and I 2 statistic. 16, 17 A RR of 1.0 or less indicates a lower rate of an outcome among patients given fish 0il than among those in the control group. We used the DerSimonian and Laird random-effect method when important and statistically significant heterogeneity existed between trials. The Mantel-Hanzel fixed-effect method was adopted when heterogeneity was negligible. We used the Review Manger (RevMan 4.2.7) statistical software provided by the Cochrane Collaboration for statistical analyses. All tests of significance were 2-sided and statistical significance was defined as p < 0.05.
Results
Trial flow
We identified 8 articles, 5 of which were excluded: 1 because it was a study rationale, 18 1 because it was a letter 19 and 3 because they were review articles [20] [21] [22] (Figure 1 ). The 3 remaining articles were randomized controlled trials and were included in our analysis. [12] [13] [14] 
Study characteristics
The 3 trials selected for analysis included patients who were similar in terms of age, sex and mean ejection fraction ( Table  1 ). The patients included in each trial had received an implantable cardioverter defibrillator because of ventricular tachycardia or ventricular fibrillation. The trials by Leaf and colleagues 13 and Brouwer and colleagues 14 included patients taking sotalol and amiodarone; however, these drugs were part of the exclusion criteria for the trial by Raitt and colleagues. 12 The study by Raitt and colleagues reported that digoxin was given to 29% of participants in the intervention group and 33% in the control group. The other 2 studies did not report digoxin use.
There were differences among the 3 studies in the number of participants and the duration of follow-up ( Table 1 ). The fish-oil dose was 2.6 g/d fish oil in the study by Leaf and colleagues, 1. colleagues and Raitt and colleagues reported scores using the New York Heart Association functional classification system. In the study by Raitt and colleagues, the extent of each patient's heart failure was specified; however, 20%-26% of participants' heart failure symptoms were not classified in the other 2 studies. In the study by Raitt and colleagues, 58% of participants in the intervention group and 62% of participants in the control group received a functional class score of III or IV. In contrast, Leaf and colleagues reported that 10% of participants in the intervention group and 6% of par-ticipants in the control group received this score, and Brouwer and colleagues reported that 11% of participants in the intervention group and 9% of participants in the control group received this score. The meaning of this difference is unclear, given the similarity in ejection fraction among all 3 studies (Table 1) . All 3 included trials were considered to be of high quality. Each trial received a Jadad Score of 5 out of 5. [12] [13] [14] The Cochrane Collaboration Scale for rating study validity indicated a low risk of bias (score of A) for all studies. 
Data synthesis
Meta-analysis of the 3 trials indicated a nonsignificant relative risk of implantable cardioverter defibrillator discharge during 1 year of fish-oil supplementation of (RR 0.93, 95% confidence interval [CI] 0.70-1.24, p = 0.63) ( Figure 2 ). None of the 3 studies reported a benefit of fish oils in their primary analysis. However, when we recalculated relative risk based on the data available from the study by Leaf and colleagues, we found a significant benefit of fish oil (RR 0.74, 95% CI 0.56-0.98, p < 0.05).
The meta-analysis of the 3 studies established significant heterogeneity (p = 0.04), therefore we also performed sensitivity analyses. We detected significant heterogeneity between the studies by Raitt and colleagues 12 and Leaf and colleagues 13 (p = 0.01). No significant heterogeneity was observed between the studies by Leaf and colleagues and Brouwer and colleagues 14 (p = 0.30) or between the studies by Raitt and colleagues and Brower and colleagues (p = 0.10). Using a fixed-effects model to pool the studies by Leaf and colleagues and Brower and colleagues, we observed a significant positive effect of fish oil on implantable cardioverter defibrillator discharge (RR 0.83, 95% CI 0.69-0.99, p = 0.04) ( Figure 3) .
We also performed a meta-analysis of all-cause mortality, which was an outcome common to all 3 studies ( Figure 4 ). The follow-up period was 1 year for the studies by Leaf and colleagues and Brouwer and colleagues, and it was 2 years for the study by Raitt and colleagues. The overall RR for all-cause mortality was not significant (RR 0.70, 95% CI 0.42-1.15, p = 0.15). In addition, the confidence intervals for each study crossed the line of unity (Figure 4) . Results of the test for heterogeneity were not significant (p = 0.29).
Interpretation
Our meta-analysis suggests that there is significant heterogeneity in response to fish-oil supplementation among patients with implantable cardioverter defibrillators. This supports the theory that although some patients may benefit from supplementation with docosahexaenoic acid and eicosapentaenoic acid, others may not benefit or may be adversely affected.
The reason for the observed differences in 1-year recurrence-free survival among the 3 randomized controlled trials is not clear. However, the differences do not appear to be related to differences in cardiac status ( Table  1) . All patients received implantable cardioverter defibrillators for "secondary prophylaxis," and the mean ejection fraction in the 3 studies was similar ( Table 1 ). In 2 of the trials, 12,13 patients with worse left-ventricular function who received fish oil appeared to have improved outcomes. A similar result was also found in a post-hoc analysis of the GISSI-Prevenzione trial. 23 It is possible that drug-nutrient interactions may be, in part, responsible for the observed differences between studies. Of the 3 trials, the 2 that showed either a benefit of fish oil 13 or no adverse events 14 included a substantial number of patients who were taking antiarrhythmic drugs (sotalol and amiodarone). Potential drug-nutrient interactions have also been proposed as a reason for the differences in response to fish oil observed between the Diet and Reinfarction Trial (DART) and the Diet and Angina Randomization Trial (DART-2). 24, 25 In the Diet and Angina Randomization Trial, β-blockers and calcium-channel blockers (nifedipine) appeared to protect against myocardial infarction in men with angina who received fish or fish oil. 25 Two recent meta-analyses failed to demonstrate a clear advantage of increased fish-oil consumption, either for secondary prevention of coronary heart disease or restenosis after angioplasty. 4, 10 In the first meta-analysis, the adverse events observed among patients with angina in the trial by Burr and colleagues 24 contributed to an overall nonsignificant effect of fish oil on secondary prevention of coronary heart disease. 4 In the second meta-analysis, despite a significant benefit in a clinical subgroup, which defined restenosis as recurrent stenosis of at least 50% in any vessel, no overall advantage was seen for fish oils in preventing restenosis after angioplasty. 10 
Figure 2:
Meta-analysis of implantable cardioverter defibrillator discharge in studies of fish-oil supplementation. Significant heterogeneity was detected between trials (p = 0.04). Note: CI = confidence interval.
omitted. 11 Nevertheless, there are extensive positive preclinical data and some individual randomized controlled trials that suggest a benefit of fish-oil supplementation. 13, [26] [27] [28] Furthermore, a recent meta-analysis found a benefit of fish-oil supplementation and found no adverse effects related to contamination of fish. 5 Despite these positive findings, recent meta-analyses of randomized controlled trials in all 3 areas related to coronary heart disease (secondary prevention, post-angioplasty restinosis, ventricular tachycardia and fibrillation) have not demonstrated a clear benefit for fish and fish oils but have shown significant between-study heterogeneity. 4, 10 The importance of randomized controlled trials of implantable cardioverter defibrillator and fish oils is that they explore a key mechanism by which omega-3 fatty acids have been suggested to confer cardiovascular benefit, namely, their direct antiarrhythmic effects. 29, 30 Trials have emphasized the early divergence of the Kaplan-Meier survival curves in secondary prevention of cardiovascular disease in studies of both fish oil and omega-3 vegetable oil. 31, 32 In these studies, the reduction in the number of coronary heart disease events started too soon after initiating supplementation to be caused by regression of arteriosclerotic lesions in coronary arteries. Furthermore, no Relative risk and 95% CI C p = 0.04 p = 0.78 p = 0.86 changes were seen in serum lipids that would be predicted to reduce atheroma formation with the use of omega-3 fatty acids from fish or vegetables.
Favours control Favours treatment
Some statin trials have shown early divergence of Kaplan-Meier curves by 1 year, and in this instance, the explanation may also not be related to atheroma regression but to plaque stabilization possibly because of statin's anti-inflammatory effects. 33, 34 A potential criticism of the implantable cardioverter defibrillator trials is that they collectively involved a relatively small number of patients compared to the GISSI-Prevenzione trial 26 or the Japan EPA Lipid Intervention study, 28 which included 11 324 and 18 645 participants respectively. The implantable cardioverter defibrillator trials included in our meta-analysis involved patients with pre-existing arrhythmia (secondary prophylaxis); however, the GISSI-Prevenzione trial and Japan EPA Lipid Intervention study were, in effect, studies of primary prophylaxis in which the mechanism of death may be quite different (e.g., ischemic ventricular fibrillation as opposed to scar-related ventricular tachycardia). In addition, in the GISSI-Prevenzione trial, early sudden death at 4 months (used as a marker for the potential anti-arrhythmic effects of fish oil) showed a significant difference favouring fish oil. However, the total number of participants at 4 months was not reported. 31 At 3 months, there were 26 sudden deaths in the fish-oil group and 37 in the control group. In comparison, implantable cardioverter defibrillator discharge occurred in a total of 398 patients in the 3 implantable cardioverter defibrillator studies (fish oil, 189; control, 209; p = 0.63) [12] [13] [14] and represents a substantially greater number of end-point events. Furthermore, the total number of all-cause deaths in these studies (n = 61) was of a similar order of magnitude to the sudden deaths in the GISSI-Prevenzione trial at 4 months, the time point at which significance was achieved. 31 The discharge of implantable cardioverter defibrillators has also been used as a surrogate marker for sudden death. Leaf and colleagues reported deaths attributed directly to arrhythmia. They reported 3 deaths in the fish oil group and 1 in the control; thus, there were too few deaths for any conclusions to be made. 13 Other studies have assessed the effect of fish-oil supplementation on cardiac rhythm in patients without implantable cardioverter defibrillators. In 2 studies that included patients with frequent premature ventricular complexes, fish-oil supplementation did not reduce the number of premature ventricular complexes. 35, 36 Among patients who had experienced myocardial infarction, fish-oil supplementation either did not reduce the number of ventricular extrasystoles 37 or it increased heart-rate variability. 38 Conclusive evidence for an antiarrhythmic benefit of fish oil in these studies is lacking; however, several studies suggest that fish oils decrease heart rate. 35, 39, 40 Yet even among these studies, the data on changes in the electrocardiographic characteristics are inconsistent. 36 Heterogeneity is an important issue in systematic reviews and meta-analyses. There are 2 main analytical approaches to dealing with heterogeneity: incorporating it into the analysis (using random-effects models) or explaining it (using meta-regression techniques or subgroup analyses, or both). Lau and colleagues 41 have provided a useful flowchart that summarizes the ways that heterogeneity is being dealt with in the systematic-review literature, which includes ignoring heterogeneity completely (i.e., using a fixed-effects model) or not pooling the data. We chose to incorporate heterogeneity using a randomeffects model, because we believed that the combined result was conservative and more honest (wider confidence intervals and larger p values), and that it reflected the uncertainty of the treatment effect. Furthermore, 1 of the studies included in our analysis appeared to be the main source of the observed heterogeneity, which led us to investigate the sensitivity of the meta-analysis results by excluding 1 study at a time. We also believed that the best approach to dealing with heterogeneity was to try to explain it using meta-regression techniques and subgroup analyses. However, because there were only 3 studies available for our meta-analysis, these approaches were not practical.
Fish oils have complex and pleiotropic effects that may affect the heart. These effects include blocking cardiac ion channels, reducing fibrosis in response to mechanical stress, 42 decreasing blood coagulation, reducing serum triglycerides 43 and possibly altering immune function. Studies in different patient populations with different pathophysiologies and therapeutic regimens have all produced divergent results. Early randomized controlled trials of secondary prevention suggested that supplementation with docosahexaenoic acid and eicosapentaenoic acid reduces cardiac events. However, more recent data suggest that caution should be exercised when analyzing data from certain subgroups, such as men with stable angina. 24 The same may also be true for data from patients with implantable cardioverter defibrillators who have a history of ventricular tachycardia and who are not taking antiarrhythmic medications. 12 The need for further research has been called for by official agencies. 6 Large randomized controlled trials are needed to address the question of controlling ventricular arrhythmia with long-chain omega-3 fatty acids. Large trials are also needed to define the effects of long-chain omega-3 fatty acids in patients with heart failure and angina. These trials must be sufficiently large or selective to address the effects of cointerventions, especially the use of antiarrhythmic drugs. In view of the biochemical block in the conversion of eicosapentaenoic acid to docosahexaenoic acid 44 and the environmental concerns over depletion of fish stocks, studies should include commercial docosahexaenoic acid from phytoplankton. This fatty acid is already being used in infant formula in Europe. 45 The use of commercial fatty acids such as docosahexaenoic acid will allow the role of this specific fatty acid to be assessed, something that cannot be done using the current mixtures. In addition, comparisons should be made using α-linolenic acid, a shorter chain-length omega-3 fatty acid from vegetable sources, which has shown promise in preventing recurrence of coronary heart disease. 32, 46 At present, the use of fish oils in patients with implantable cardioverter defibrillators appears to warrant caution.
